---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-23-000059"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:07:34.536971+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Guardant Health Q1 revenue up 34% to $128.7M; raises FY2023 guidance to $535-545M

## Summary
- Revenue $128.7M (+34% YoY); clinical tests 39,100 (+45%), biopharma tests 6,150 (+21%).
- Net loss $133.5M ($1.30/share) vs $123.2M ($1.21) prior year; non-GAAP net loss $108.5M ($1.06).
- Gross margin 59% (down from 67%) on mix shift; operating expenses $209.7M (+12%).
- FY2023 revenue guidance raised to $535-545M (prev $525-540M); expects FCF outflow ~$350M.
- Appointed Ines Dahne-Steuber COO and promoted Darya Chudova CTO; Shield CRC screening PMA under FDA review.

## SEC filing metadata
- accession: 0001576280-23-000059
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000059/0001576280-23-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000059/gh-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-23-000059
- JSON: https://secwatch.observer/filing/0001576280-23-000059.json
- Plain text: https://secwatch.observer/filing/0001576280-23-000059.txt

## Key facts
- Earnings Releases
  Guardant Health, Inc. reported the fiscal quarter and year ended March 31, 2023 results: revenue $128.7 million, net income Net loss was $133.5 million, EPS Net loss per share was $1.30. Guidance raised.
  - Period: the fiscal quarter and year ended March 31, 2023
  - Revenue: $128.7 million
  - Net income: Net loss was $133.5 million
  - EPS: Net loss per share was $1.30
  - Guidance: raised
  - Result: reported results
  source text: tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2023. First Quarter 2023 Financial Highlights • Revenue of $128.7 million for the first quarter of 2023, an increase of 34% over the first quarter of 2022 • Reported 39,100 tests to clinical customers and 6,150 tests to biopharmaceutical customers in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000059/0001576280-23-000059-index.htm
- Earnings Releases
  Guardant Health, Inc. reported the quarter ended March 31, 2023 results: revenue $128.7 million, net income net loss was $133.5 million, EPS Net loss per share was $1.30. Guidance raised.
  - Period: the quarter ended March 31, 2023
  - Revenue: $128.7 million
  - Net income: net loss was $133.5 million
  - EPS: Net loss per share was $1.30
  - Guidance: raised
  - Result: reported results
  source text: tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2023. First Quarter 2023 Financial Highlights • Revenue of $128.7 million for the first quarter of 2023, an increase of 34% over the first quarter of 2022 • Reported 39,100 tests to clinical customers and 6,150 tests to biopharmaceutical customers in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000059/0001576280-23-000059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.